ASSOCIATION BETWEEN BIOACTIVE MOLECULES IN BREAST MILK AND TYPE 1 DIABETES MELLITUS

Tajudeen Yahaya1 and Ufuoma Shemishere2

ABSTRACT: The association between breastfeeding and type 1 diabetes mellitus (T1DM) is controversial. However, several recent studies have established a link between these two factors, necessitating a need to review this subject to raise public awareness. Current research indicates that breast milk contains a variety of bioactive substances including immunoglobulins, oligosaccharides, insulin, lactoferrin, lysozyme, cytokines, epidermal growth factors, leukocytes, nucleotides, beneficial bacteria and vitamins. Such substances strengthen the breastfeeding infant’s immune system, both directly, by increasing gut microbiota diversity and attacking harmful bacteria and pro-inflammatory molecules, and indirectly, by increasing thymus performance. Accordingly, a lack of or inadequate breastfeeding may predispose infants to several autoimmune disorders, including T1DM. Nursing mothers and caregivers are therefore advised to follow optimal breastfeeding practices prior to introducing complementary foods.

Keywords: Breastfeeding; Type 1 Diabetes Mellitus; Autoimmune Diseases; Immunoglobulins; Oligosaccharides; Review Literature.

Introduction

Type 1 diabetes mellitus (T1DM) is a long-term degenerative disease that begins when the body’s defense mechanism starts to destroy its own pancreatic β-cells.1,2 While the exact etiology of the disease is unknown, several triggers are thought to play a role in disease causation, including genetic, epigenetic and environmental factors. Previously, T1DM was thought to affect only children and thus termed juvenile or childhood diabetes mellitus; however, as a result of technological advancements in diagnostic tools, it is now understood that it occurs at any age.1,2 Currently, the disease is known to affect only children and thus termed type 1 diabetes mellitus (T1DM) and is characterized by severe insulin deficiency and hyperglycaemia.3 Early symptoms include increased thirst, appetite and weakness, frequent urination and weight loss.4 Uncontrolled hyperglycaemia may subsequently result in multiorgan damage involving the eyes, kidneys, nerves and heart, among other organs.5 Unfortunately, there is no cure for the disease yet; as such, affected patients need to self-medicate and take daily doses of insulin for survival.4 Although type 2 DM (T2DM) accounts for the majority of the overall economic burden of DM due to its higher prevalence, the economic burden is greater on individual patients with T1DM.6

Overall, the prevalence of T1DM is rising steadily, with an annual global increase of over 3%, which is projected to double in the next 20 years.7 For many European and North American countries, the rising incidence of T1DM began around the mid-20th century, coinciding with increased industrialisation.8 Among other lifestyle modifications, breastfeeding patterns...
changed due to the introduction of infant feeding alternatives such as formula. The loss of immunological function due to inadequate or inappropriate breastfeeding habits may contribute to the rising incidence of T1DM. This review therefore aimed to examine the association between T1DM and the immunological function of bioactive molecules in breast milk.

Association of Bioactive Molecules with Breastfeeding

The role of breast milk in the aetiology and prevention of T1DM is controversial, with certain studies showing a protective effect and others reporting predisposing or no effects at all. In a meta-analysis of 25 studies with 226,508 participants from 12 countries, Yan et al. found that breastfeeding resulted in a reduced risk of DM triggers. Importantly, 17 of these studies indicated a dose-response relationship between breastfeeding duration and a lowered risk of childhood obesity. In another meta-analysis involving 155,392 Norwegian and Danish children, Lund-Blix et al. reported that T1DM was related to the early introduction of infant formula, with non-breastfed children having a two-fold increased risk of disease compared to those who were breastfed. Nevertheless, in a meta-analysis involving 43 observational studies of 9,874 individuals with T1DM, Cardwell et al. observed a weak link between exclusive breastfeeding and T1DM. Many factors, particularly the experimental designs of these studies and variations in breastfeeding patterns in different countries, could be responsible for these inconsistent results. However, studies that report weak or negative effects usually monitor breastfeeding to an imprecise degree, without considering whether breastfeeding is exclusive or complementary.

Exclusive breastfeeding without vitamin supplementation may cause vitamin D deficiency in infants, particularly if the mother herself is deficient. It may also result in vitamin E deficiency as vitamin E content in breast milk decreases as colostrum matures. Vitamin E scavenges free radicals, blocking infiltrating toxins and cytokines and protecting cells, including the pancreatic islet cells. Deficiencies of both vitamins may play a role in the pathogenesis of T1DM. Giulietti et al. reported the overexpression of pro-inflammatory cytokines, reduced thymus performance and pancreatic islet dysfunction in non-obese diabetic mice kept away from ultraviolet light and fed with a vitamin D-depleted diet. In a Finnish birth cohort study, Hyppönen et al. found that daily supplementation of 200 IU of vitamin D was associated with a lower incidence of T1DM among children. In a prospective clinical study of both T1DM and T2DM patients, vitamin E supplementation decreased blood glucose levels and reduced the progression of the disease.

According to Virtanen et al., complementary feeding may yield no effect if this feeding consists of dietary formulas containing certain complex proteins. Similarly, Chia et al. showed that dietary A1 β-casein may affect glucose homeostasis and induce progression to T1DM in non-obese diabetic mice. Gluten in cereals is also linked with increased T-cell reactivity, with diabetogenic effects in rodents. Additionally, breastfeeding from containers, which are often coated with preservatives and anti-rust agents such as bisphenol A (BPA), may affect breastfeeding outcomes. In a study of new and used baby bottles in Iran, BPA levels ranged from 0.49–8.58 μg/L and 0.63–2.47 μg/L, respectively. In pregnant rats, BPA doses as low as 0.5 μg/L were found to induce persistent islet insulin hypersecretion for up to one year.

The duration of breastfeeding and the age at which complementary foods are administered may also determine the protective role or otherwise of breast milk on T1DM pathogenesis. Short-term breastfeeding (<3 months) and the early or late introduction of complementary foods (<4 months and ≥6 months, respectively) are risk factors for T1DM. Additionally, the introduction of cereals before three months of age may be related to early β-cell autoimmunity. Furthermore, certain maternal factors and prenatal lifestyle choices such as tobacco smoking, age, mode of birth and psychological stress levels may predispose an infant to T1DM. These factors may also be linked to breastfeeding outcomes.

Mechanistic Links

Breast milk has been found to contain various anti-pathogenic and anti-inflammatory bioactive molecules, some of which can confer infants with lifelong immunity against many diseases, including T1DM. Thus, breast milk can be described as a medium through which the maternal defense mechanism trains the immune system of the infant. Established mechanisms through which breast milk prevents T1DM and other autoimmune diseases are outlined in Table 1.

REDUCED GUT PERMEABILITY AND PRIMING OF THE IMMUNE SYSTEM

The diversity of the gut microbiota—the composition of which is influenced by various environmental factors such as diet and lifestyle—is important in the aetiology and prevention of T1DM. Homeostatically imbalanced microbiota, as characterised by a high preponderance of certain bacteria, increases intestinal permeability, eliciting autoantibodies and causing β-cell auto-
In experimental mice, microbiota imbalance was found to decrease tolerance to food antigens and the proportions of regulatory T-cells (Tregs) in the intestinal lamina propria, causing intestinal inflammation. This results in high intestinal permeability, inducing insulitis or allowing more exogenous antigens into the mucosal immune system. Studies of obese and non-obese diabetic mice have observed that this leads to increased cytokine production that may attack and damage pancreatic β-cells. Bacterial metabolites may also attack the pancreatic islet directly. This was shown during a study of mice in which Streptomyces-derived toxins impaired glucose tolerance, reducing islet size and β-cell mass at low doses via adenosine triphosphatase inhibition.

The innate immune system—body’s first defence mechanism after birth—is weak and lacks important components. In healthy infants, a developing gut microbiome undergoes several stages of maturation in which the ingestion of breast milk is considered the most important factor. This is possible because breast milk contains many beneficial bacteria and bioactive molecules. Diverse groups of beneficial bacteria in breast milk reduce gut permeability, promote gut microbiota diversity and maturation as well as boost immunological and metabolic function.

Breast milk contains high levels of Lactobacillus and Bifidobacterium species, which promote the growth of Firmicutes bacteria. Firmicutes deficiency has been reported in individuals with T1DM. Bacteroides species are also present in breast milk and increase gut diversity and maturation. Gut bacteria achieve these functions in vitro by either naturally killing pathogenic bacteria during the competition for food and survival or by producing antimicrobial effects.

Insulin is another bioactive molecule found in breast milk; this hormone enhances gut maturation and reduces gut permeability to macromolecules. In addition, insulin in breast milk may induce tolerance to blood insulin and prevent T1DM pathogenesis. Breast milk insulin enhances the diversity of the gut microbiota by boosting the growth of some members of the Gammaproteobacteria family and reducing the Streptococcaceae population. Gammaproteobacteria are involved in the maturation of infant gut microbiota, primarily in the first week after birth. Insulin and leptin, another hormone in breast milk, also influence gut microbiota diversity by suppressing certain microbial metabolic pathways associated with intestinal inflammation while promoting beneficial ones.

Oligosaccharides are non-digestible sugars in breast milk that promote the growth of protective bacteria in the colon. The non-digestible properties of oligosaccharides allow these molecules to escape the acidic medium of the small intestine into the colon.

| Category                        | Molecule                  | Potential roles                                      |
|---------------------------------|---------------------------|-----------------------------------------------------|
| **Adipokines**                  | Leptin, Adiponectin       | Antimicrobial function, immune modulation, increased β-cell function |
| **Immunoglobulins**            | IgA, IgG                  | Antimicrobial function, anti-inflammatory function, immune modulation |
| **Hormones**                   | Insulin, Lactoferrin, Lysozyme, Corticosteroids | Anti-inflammatory function, strengthened immunity, increased thymus performance |
| **Maternal immune cells**      | Leukocytes, Stem cells, CD4+, miRNAs | Antimicrobial function, strengthened immunity, increased thymus performance |
| **Growth factors**             | EGFs, IGF                 | Immune modulation, increased β-cell mass, Pancreatic morphogenesis |
| **Cytokines**                  | IL-1, IL-6, IL-7          | Anti-inflammatory function, immune modulation, increased thymus size |
| **Beneficial bacteria**        | Lactobacillus sp., Bifidobacterium spp., Firmicutes spp. | Anti-infectious function, increased gut diversity, strengthened immunity |
| **Nutrients**                  | Oligosaccharides, Triglycerides, Vitamins, Minerals | Increased gut diversity, anti-microbial function, immune modulation |

**Table 1: Bioactive molecules in breast milk and their role in type 1 diabetes mellitus risk reduction**

Immunity, the hallmark of T1DM, Individuals with T1DM have less stable and diverse microbiota compared to non-diabetics. The most frequently reported microbiome imbalance in diabetic individuals is a decreased Firmicutes population with a corresponding increase in the Bacteroides genus, the opposite of which is usual in non-diabetics.
where they produce short-chain fatty acids. These fatty acids enhance the growth of probiotic species, including Lactobacillus and Bifidobacterium, resulting in a balanced microbiome. In an *in vitro* study, oligosaccharides were found to inhibit and block harmful intestinal microorganisms from binding to their normal targets in the epithelial cells, thus reducing their population. Oligosaccharides were also reported to confer a protective effect in a murine model of T1DM. The administration of oligosaccharides was shown to influence microbiota diversity and produce short-chain fatty acids in non-obese diabetic mice, reversing DM progression.

Breast milk also contains large quantities of secretory immunoglobulin (Ig) A, which accounts for the majority of the Igs in human breast milk. Besides IgA, there are four other types of Igs in breast milk: IgE, IgG, IgM and IgD. Breast milk secretory IgA helps train the immune system of newborns against enteric pathogens acquired through maternal exposure. Breast milk also contains certain bioactive substances capable of stimulating IgA secretion in infants. Secretory IgA can neutralise infectious agents and reduce the inflammatory effects of other antibodies. Some children with DM are both IgA- and IgG-deficient.

Lactoferrin, an iron-binding glycoprotein, possesses several anti-infective properties that form part of the innate defense mechanism conferred by mature human breast milk. Lactoferrin has a high binding affinity for iron, thus limiting its availability to bacteria and other microorganisms. In the intestine, lactoferrin may bind to certain receptors, such as toll-like receptors (TLRs) and the *cluster of differentiation (CD)*14 gene, thereby blocking the attachment of pathogens to the intestinal epithelium. In the stomach, lactoferrin combines with pepsin to form lactoferrincin, an antimicrobial agent blocking the attachment of bacteria to the mucosal epithelium. Lactoferrin is of particular importance, as these factors aid in the healing and maturation of the intestinal mucosa, nervous system and endocrine system, among others.

Breast milk, particularly *colostrum*, contains high concentrations of leukocytes, of which approximately 10% are lymphocytes, T-cells, macrophages, neutrophils and antibody-producing B-cells. These cells survive passage into the newborn intestines, where they phagocytise microbial pathogens and strengthen the infant's immune response. Triglycerides are also an important component of breast milk. The newborn stomach digests triglycerides using lingual and gastric lipases, releasing free fatty acids and monoglycerides. These two products strengthen the immune system and —through their lytic activities— protect the newborn from various viruses, bacteria and some protozoa, specifically those of the *Giardia* family. Nucleotides are also present in human breast milk and enhance immune function in infants. Finally, apart from vitamin D, breast milk contains sufficient quantities of all vitamins essential for normal growth in children.

**ENHANCED THYMUS SIZE AND FUNCTION**

During both the fetal and neonatal periods, the primary function of the thymus is to assist in the development and maturation of T-lymphocytes or T-cells. This specific type of white blood cell protects the body from microbial infections and other risks by either controlling immune reactions or directly attacking infected or cancerous cells. After puberty, the thymus reduces its function and slowly decreases in size until it is replaced by fat at about 75 years of age. Nevertheless, during its active phase, the thymus produces enough T-cells to protect the body from autoimmune life.

Due to its role in maintaining a strong neonate defence mechanism, loss of thymus function may be implicated in the pathogenesis of several diseases. For instance, autoimmune-mediated DM begins with the failure of the thymus to develop a normal β-cell self-tolerance. Dysfunctional thymic activity along with expression of insulin-like growth factor 2 is also suspected in certain cases of insulin resistance. One animal study noted the development of autoimmune
diseases in mice whose thymuses were removed. While scientists are still skeptical about the role of thymus size in its performance, the fact that the organ is largest during childhood when an individual is most prone to immunological threats seems to indicate that increased thymus size is associated with better immunity.

Several factors may influence thymus size and activity, potentially leading to the prevention of autoimmune diseases such as T1DM. Some studies show that breast milk may enlarge the thymus gland, either directly via certain components in breast milk or indirectly as a result of the effects of breast milk on infant gut microbiota. Breast milk contains CD4+ T-cells, which are passed into the thymus of the infant where they help train CD8+ T-cells to fight pathogens. Breast milk also contains maternal cytotoxic T-lymphocytes which pass into the thymus of infants, after which they find their way to the lymphatic tissues in the ileum where they prevent the growth of harmful bacteria.

Microribonucleic acids (miRNAs) that regulate post-transcription immune cell activity are also present in breast milk. Notably, miRNA-155 plays a key role in regulating thymus Treg and T-helper-2 cell development in humans and animals. In mice, miRNA-449a regulates thymus medullary epithelial cell development. Certain hormones involved in thymus development are also present in breast milk. Among these are corticosteroids, which control thymus epithelial differentiation and the production of thymus corpuscles. In addition, IL-7 is also present in breast milk and regulates thymus size. Collinson et al. reported that the children of malnourished mothers have small thymuses, with small thymus size linked with low IL-7 levels in maternal breast milk.

**Conclusion**

Breast milk contains a wide variety of bioactive substances which functionally protect the infant’s immune system from autoimmune disorders by increasing the population of beneficial bacteria in the gut, attacking pathogenic bacteria and pro-inflammatory molecules as well as increasing thymus size and performance. As such, inadequate breastfeeding may predispose an infant to autoimmune diseases, including T1DM. Nursing mothers and caregivers are therefore advised to follow optimal breastfeeding practices. For babies unable to be breastfed, perhaps due to maternal death or the risk of vertical disease transmission, the bioactive substances mentioned in breast milk can be used to formulate infant feeding formula for such babies.

**References**

1. Kalathi D, James S, Zaidi R. Diagnosis and management of type 1 diabetes mellitus. Clin Pharm 2018; 10.1. https://doi.org/10.2111/CP.2018.20.205044.
2. Thomas NJ, Jones SE, Weedon MN, Weedon MN, Shields BM, Oran RA, et al. Frequency and phenotype of type 1 diabetes in the first six decades of life: A cross-sectional, genetically stratified survival analysis from UK Biobank. Lancet Diabetes Endocrinol 2018; 6:122–9. https://doi.org/10.1016/S2213-8587(17)30362-5.
3. Soltész G, Patterson CC, Dahlquist G. EURODIAB Study Group. Worldwide childhood type 1 diabetes incidence: What can we learn from epidemiology? Pediat Diabetes 2007; 8:6–14. https://doi.org/10.1111/j.1399-5548.2007.00280.x.
4. Redondo MJ, Libman I, Cheng P, Kollman C, Tosur M, Gal RL, et al. Racial/ethnic minority youth with recent-onset type 1 diabetes have poor prognostic factors. Diabetes Care 2018; 41:1017–24. https://doi.org/10.2337/dc17-2335.
5. Burrack AL, Martinov T, Fife BT. T cell-mediated beta cell destruction: Autoimmunity and alloimmunity in the context of type 1 diabetes. Front Endocrinol (Lausanne) 2017; 8:343. https://doi.org/10.3389/fendo.2017.00043.
6. Kahanovitz L, Sluss PM, Russell SJ. Type 1 diabetes: A clinical perspective. Point Care 2017; 16:37–40. https://doi.org/10.1097/POC.0000000000000125.
7. International Diabetes Federation. About diabetes: Diabetes complications. From: www.idf.org/aboutdiabetes/complicatio ns.html Accessed: Oct 2019.
8. Grose DN, O’Brien CL, Rongetti EK, Corcoran HM, Loh MM, Ward GM, et al. Living with type 1 diabetes and an insulin pump: A qualitative insight. Pract Diabetes Int 2018; 35:2187. https://doi.org/10.1002/pdi.2187.
9. Tao R, Pietropaolo M, Atkinson M, Schatz D, Taylor D. Estimating the cost of type 1 diabetes in the U.S.: A propensity score matching method. PLoS One 2010; 5:e11501. https://doi.org/10.1371/journal.pone.0011501.
10. Patterson CC, Harjutsalo V, Rosenberg J, Nen A, Cinek O, Skrivarhaug T, et al. Trends and cyclical variation in the incidence of childhood type 1 diabetes in 26 European centres in the 25 year period 1989-2013. A multicentre prospective registration study. Diabetologia 2019; 62:408–17. https://doi.org/10.1007/s00125-018-4763-3.
11. Harjutsalo V, Sjöberg L, Tuomilehto J. Time trends in the incidence of type 1 diabetes in Finnish children: A cohort study. Lancet 2008; 371:1777–82. https://doi.org/10.1016/S0140-6736(08)60765-5.
12. Gale EA. The rise of childhood type 1 diabetes in the 20th century. Diabetes 2002; 51:3553–61. https://doi.org/10.2337/ diabetes.51.12.3553.
13. Yan J, Liu L, Zhu Y, Huang G, Wang PP. The association between breastfeeding and childhood obesity: A meta-analysis. BMC Public Health 2014; 14:1267. https://doi.org/10.1186/1471-2458-14-1267.
14. Lund-Blix NA, Dyrekong Sander S, Svardal K, Nybo Andersen AM, Rønningen KS, Joner G, et al. Infant feeding and risk of type 1 diabetes in two large Scandinavian birth cohorts. Diabetes Care 2017; 40:920–7. https://doi.org/10.2337/dc17-0016.
15. Cardwell CR, Sterne LC, Ludvigsson J, Rosenberg J, Cinek O, Svensson J, et al. Breast-feeding and childhood-onset type 1 diabetes: A pooled analysis of individual participant data from 43 observational studies. Diabetes Care 2012; 35:2215–25. https://doi.org/10.2337/dc12-0438.
16. Dawodu A, Tsang RC. Maternal vitamin D status: Effect on milk vitamin D content and vitamin D status of breastfeeding infants. Adv Nutr 2012; 3:353–61. https://doi.org/10.3945/an.111.009590.
Association between Bioactive Molecules in Breast Milk and Type 1 Diabetes Mellitus

17. Silva AL, Ribeiro KD, Melo LR, Bezerra DF, de Queiroz JL, Lima MS, et al. Vitamin E in human milk and its relation to the nutritional requirement of the term newborn. Rev Paul Pediatr 2017; 35:156–64. https://doi.org/10.1590/1984-0462/2017;35;200015.

18. Al-Agha AE, Ahmad IA. Association among vitamin D deficiency, type 1 diabetes mellitus and glycemic control. J Diabetes Metab 2015; 6:1000594. https://doi.org/10.4172/2155-6156.1000594.

19. Komisaenko YL, Bobrykh ML. Vitamin D deficiency and immune disorders in combined endocrine pathology. Front Endocrinol (Lausanne) 2018; 9:6600. https://doi.org/10.3389/fendo.2018.00600.

20. Giulietti A, Gysemans C, Stoofels K, van Etten E, Decallonne B, Overbergh L, et al. Vitamin D deficiency in early life accelerates type 1 diabetes in non-obese diabetic mice. Diabetologia 2004; 47:451–62. https://doi.org/10.1007/s00125-004-1329-3.

21. Hyppönen E, Läärä E, Reunanen A, Järvelin MR, Virtanen SM. Intake of vitamin D and risk of type 1 diabetes: A birth-cohort study. Lancet 2001; 358:1500–3. https://doi.org/10.1016/S0140-6736(00)05880-1.

22. Baburao Jain A, Anand Jain V. Vitamin E, its beneficial role in diabetes and complications. J Diagn Res 2012; 6:1624–8. https://doi.org/10.4103/0973-2630.12/2011.3625.

23. Virtanen SM, Läärä E, Hyppönen E, Rejonen H, Räsänen L, Aro A, et al. Cow’s milk consumption, HLA-DQBI genotype, and type 1 diabetes: A nested case-control study of siblings of children with diabetes - Childhood diabetes in Finland study group. Diabetes 2000; 49:912–17. https://doi.org/10.2373/diabetes.49.6.912.

24. Chia JS, McRae JL, Enjapoori AK, Lefèvre CM, Kukuljan S, Chia JS, et al. Dietary cow’s milk protein A1 beta-casein increases the incidence of T1D in NOD mice. Nutrients 2018; 10:1291. https://doi.org/10.3390/nu100101291.

25. Scott FW, Rowseil P, Wang GS, Borghardt K, Kolb H, Flöbe S. Oral exposure to diabetes-promoting food or immunomodulators in neonates alters gut cytokines and diabetes. Diabetes 2002; 51:73–8. https://doi.org/10.2373/diabetes.51.1.73.

26. Moghadam ZA, Mirlohi M, Pourzamani H, Malekpour A, Scott FW, Rowsell P, Wang GS, Burghardt K, Kolb H, Flohé S. Developmental exposure to a very low dose of bisphenol A affects the immune development and increase disease incidence in a spontaneous mouse model of autoimmune insulin-dependent diabetes. PLoS One 2015; 10:e125448. https://doi.org/10.1371/journal.pone.0125448.

27. Pannaraj PS, Li F, Cerini C, Bender JM, Yang S, Rollie A, et al. Association between breast milk bacterial communities and establishment and development of the infant gut microbiome. JAMA Pediatr 2017; 171:647–54. https://doi.org/10.1001/jamapediatrics.2017.0378.

28. Shebahad N, Shamir R, Berant M, Etzioni A. Insulin in human milk and the prevention of type 1 diabetes. Pediatr Diabetes 2002; 2:175–7. https://doi.org/10.1034/j.1399-5448.2002.012004.x.

29. Leman DJ, Young BE, Baker PR 2nd, Tomcik AC, Soderberg TK, Hernandez TL, et al. Alterations in human milk leptin and insulin are associated with early changes in the infant intestinal microbiome. Am J Clin Nut 2016; 103:1291–300. https://doi.org/10.3945/ajcn.115.126375.

30. Eggesbo M, Moen B, Peddala S, Baird D, Bugvist I, Midvedt T, et al. Development of gut microbiota in infants not exposed to medical interventions. APMIS 2011; 119:17–35. https://doi.org/10.1111/j.1600-0463.2010.02688.x.

31. Triantis V, Bode L, van Neeve RN. Immunological effects of human milk oligosaccharides. Front Pediatr 2018; 6:190. https://doi.org/10.3389/fped.2018.00190.

32. Mehta R, Petrova A. Biologically active breast milk proteins in association with very preterm delivery and stage of lactation. J Perinatol 2011; 31:58–62. https://doi.org/10.1038/jp.2010.68.

33. Cacho NT, Lawrence RM. Innate immunity and breast milk. Front Immunol 2017; 8:584. https://doi.org/10.3389/fimmu.2017.00584.

34. Field CJ. The immunological components of human milk and their effect on immune development in infants. J Nutr 2005; 135:1–4. https://doi.org/10.1093/jn/135.1.1.

35. Guðný E, Wong FS, Wen L. The gut microbiota and type 1 diabetes. Clin Immunol 2015; 159:143–53. https://doi.org/10.1016/j.clim.2015.05.013.

36. Fassatiou M, Lopez-Siles M, Díaz-Rizzo DA, Jmel H, Naouali C, Abdessalem G, et al. Gut microbiota imbalances in Tunisian participants with type 1 and type 2 diabetes mellitus. BioSci Rep 2019; 39:BSR20182348. https://doi.org/10.1042/BSR20182348.

37. Candon S, Perez-Arroyo A, Marquet C, Valette F, Foray AP, Pelletier B, et al. Antibiotics in early life alter gut microbiome and increase disease incidence in a spontaneous mouse model of autoimmune insulin-dependent diabetes. PLoS One 2015; 10:e125448. https://doi.org/10.1371/journal.pone.0125448.

38. Lönnerdal B. Bioactive proteins in breast milk. J Paediatr Child Health 2013; 49:1–7. https://doi.org/10.1111/jpc.12104.

39. Field CJ. The immunological components of human milk and their effect on immune development in infants. J Nutr 2005; 135:1–4. https://doi.org/10.1093/jn/135.1.1.
51. Kimpimäki T, Erikkola M, Korhonen S, Kupila A, Virtanen SM, Ilonen J, et al. Short-term exclusive breastfeeding predisposes young children with increased genetic risk of type 1 diabetes to progressive beta-cell autoimmunity. Diabetologia 2001; 44:63–9. https://doi.org/10.1007/s001250051581.

52. Neuburg DS, Walker WA. Protection of the neonate by the innate immune system of developing gut and of human milk. Pediatr Res 2007; 61:2–8. https://doi.org/10.1203/pdr.0p0000000000002574.

53. Pickering LK, Granoff DM, Erickson JR, Masor ML, Cordle CT, Schaller JP, et al. Modulation of the immune system by human milk and infant formula containing nucleotides. Pediatrics 1998; 101:242–9. https://doi.org/10.1542/peds.101.2.242.

54. viš Streym S, Højskov CS, Møller UK, Heickendorff L, Vestergaard P, Mosekilde L, Rejmark L. Vitamin D content in human breast milk: A 9-mo follow-up study. Am J Clin Nutr 2016; 103:107–14. https://doi.org/10.3945/ajcn.115.115105.

55. Ghosh MK, Nguyen V, Muller HK, Walker AM. Maternal milk and vitamin D activity of Lactobacillus spp. isolated from breast milk on gastrointestinal pathogenic bacteria of nosocomial origin. Anaerobe 2011; 17:474–7. https://doi.org/10.1016/j.anaerobe.2011.07.008.

56. Lee AS, Gibson DL, Zhang Y, Sham HP, Vallance BA, Dutz JP. Maternal milk: A natural modulator. J Pediatr 2016; 173:S10–15. https://doi.org/10.1016/j.jpeds.2016.02.071.

57. Cani PD, Possemiers S, Van de Wiele T, Guiot Y, Everard A, Giongo A, Gano KA, Crabb DB, Mukherjee N, Novelo LL, Ghosh MK, Nguyen V, Muller HK, Walker AM. Maternal milk and vitamin D activity of Lactobacillus spp. isolated from breast milk on gastrointestinal pathogenic bacteria of nosocomial origin. Anaerobe 2011; 17:474–7. https://doi.org/10.1016/j.anaerobe.2011.07.008.

58. Maffeis C, Martina A, Corradi M, Quarella S, Nori N, Torriani S, Lee AS, Gibson DL, Zhang Y, Sham HP, Vallance BA, Dutz JP. Maternal milk: A natural modulator. J Pediatr 2016; 173:S10–15. https://doi.org/10.1016/j.jpeds.2016.02.071.

59. Maffeis C, Martina A, Corradi M, Quarella S, Nori N, Torriani S, Lee AS, Gibson DL, Zhang Y, Sham HP, Vallance BA, Dutz JP. Maternal milk: A natural modulator. J Pediatr 2016; 173:S10–15. https://doi.org/10.1016/j.jpeds.2016.02.071.

60. Mohamed WA, Schaalan MF. Anti-diabetic efficacy of lactoferrin in type 2 diabetic patients: Controlling impact on PPAR-γ, SIRT-1, and TLR4 downstream signaling pathway. Diabetol Metab Syndr 2018; 10:89. https://doi.org/10.1186/s12988-018-0390-x.

61. Soto A, Martín V, Jiménez E, Mader I, Rodríguez JM, Fernández L. Lactoferrin gene knockdown leads to similar effects to iron chelation in human adipocytes. J Cell Mol Med 2014; 18:391–5. https://doi.org/10.1111/jcmm.12234.

62. Norenberg B. Bioactive proteins in human milk: Mechanisms of action. J Pediatr 2010; 156:S26–30. https://doi.org/10.1016/j.jpeds.2009.11.017.

63. Sargis RM. An overview of the thymus: The gland that protects you long after it’s gone. From: www.endocrineweb.com/endocrinology/overview-thymus Accessed: Oct 2019.

64. World Health Organization. Training for the health sector: Immune diseases and children. From: www.who.int/cehi/capa_city/immune_diseases.pdf?ua=1 Accessed: Oct 2019.

65. Dietert RR, Piepenbrink MS. Perinatal immunotoxicity: Why adult exposure assessment fails to predict risk. Environ Health Perspect 2006; 114:477–83. https://doi.org/10.1289/ehp.8566.

66. Millionaire M, Schaller JP, et al. Modulation of the immune system by human milk: A natural modulator. J Pediatr 2016; 173:S10–15. https://doi.org/10.1016/j.jpeds.2016.02.071.

67. Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunological properties. Cell Mol Life Sci 2005; 62:2588–98. https://doi.org/10.1007/s00018-005-5373-z.

68. Legrand D. Overview of lactoferrin as a natural immune modulator. J Pediatr 2016; 173:S10–15. https://doi.org/10.1016/j.jpeds.2016.02.071.

69. Ali BA, Sayed MA, Monens HM, Mahmoud MM. Assessment of serum levels of immunoglobulin A and immunoglobulin B in children newly diagnosed with type 1 diabetes mellitus (T1D).Curr Pediatr Res 2017; 21:67–31.

70. Yamauchi K, Tomita M, Giehl TJ, Ellison RT 3rd. Antibacterial activity of lactoferrin and a pepsin-derived lactoferrin peptide fragment. Infect Immun 1993; 61:719–28.

71. Gifford JL, Hunter VN, Vogel HF. Lactoferricin: A lactoferrin-derived peptide with antimicrobial, antiviral, antitumor and immunological properties. Cell Mol Life Sci 2005; 62:2588–98. https://doi.org/10.1007/s00018-005-5373-z.

72. Sargent RM. An overview of the thymus: The gland that protects you long after it’s gone. From: www.endocrineweb.com/endocrinology/overview-thymus Accessed: Oct 2019.

73. World Health Organization. Training for the health sector: Immune diseases and children. From: www.who.int/cehi/capa_city/immune_diseases.pdf?ua=1 Accessed: Oct 2019.

74. Ngom PT, Collinson AC, Fido-Lopez J, Hensom SM, Prentice AM, Aspinall R. Improved thymic function in exclusively breastfed infants is associated with higher interleukin 7 concentrations in their mothers’ breast milk. Am J Clin Nutr 2004; 80:722–8. https://doi.org/10.1093/ajcn/80.3.722.

75. Pannaraj PS, Li F, Cerini C, Rendler JM, Yang S, Rollie A, et al. Association between breast milk bacterial communities and establishment and development of the infant gut microbiome. JAMA Pediatr 2017; 171:647–54. https://doi.org/10.1001/jamapediatrics.2017.0378.
84. Cabinian A, Sinsimer D, Tang M, Zumba O, Mehta H, Toma A, et al. Transfer of maternal immune cells by breastfeeding. Maternal cytotoxic T lymphocytes present in breast milk localize in the Peyer’s patches of the nursed infant. PLoS One 2016; 11:e0156762. https://doi.org/10.1371/journal.pone.0156762.

85. Melnik BC, John SM, Schmitz G. Milk: An exosomal microRNA transmitter promoting thymic regulatory T cell maturation preventing the development of atopy? J Transl Med 2014; 12:43. https://doi.org/10.1186/s1479-5876-12-43.

86. Kohlhaas S, Garden OA, Scudamore C, Turner M, Odlendhaug K, Vigorito E. Cutting edge: The Foxp3 target miR-155 contributes to the development of regulatory T cells. J Immunol 2009; 182:2578-82. https://doi.org/10.4049/jimmunol.0803162.

87. Alsaweed M, Hartmann PE, Geddes DT, Kakulas F. MicroRNAs in breastmilk and the lactating breast: Potential immunoprotectors and developmental regulators for the infant and the mother. Int J Environ Res Public Health 2015; 12:13981–4020. https://doi.org/10.3390/ijerph121113981.

88. Chen P, Zhang H, Sun X, Hu Y, Jiang W, Liu Z, et al. MicroRNA-449a modulates medullary thymic epithelial cell differentiation. Sci Rep 2017; 7:15915. https://doi.org/10.1038/s41598-017-16162-2.

89. Hale LP, Markert ML. Corticosteroids regulate epithelial cell differentiation and Hassall body formation in the human thymus. J Immunol 2004; 172:617–24. https://doi.org/10.4049/jimmunol.172.1.617.

90. Pundir S, Wall CR, Mitchell CJ, Thorstensen EB, Lai CT, et al. Variation of human milk glucocorticoids over 24-hour period. J Mammary Gland Biol Neoplasia 2017; 22:85–92. https://doi.org/10.1007/s10911-017-9375-x.

91. Collinson AC, Moore SE, Cole TJ, Prentice AM. Birth season and environmental influences on patterns of thymic growth in rural Gambian infants. Acta Paediatr 2003; 92:1014–20. https://doi.org/10.1111/j.1651-2227.2003.tb02568.x.